Introduction
Total hip replacement (THR) is one of the most common orthopedic procedures, with more than 100,000 primary implantations in France in 2001 [1] . Frequency and the functional benefit testified to by the patients have made it so popular as to seem sometimes ''banal''. However, it is not free of complications. Postoperative anemia, while often considered harmless, is in fact a cause of serious morbidity [2, 3] : decompensation of chronic ischemic pathologies, delayed resumption of activity, prolonged rehabilitation with resultant loss of independence, reduced quality of life and significantly increased financial cost.
The European multi-center OSTHEO study [4] , involving 225 hospitals and 2640 primary THR patients, quantified perioperative blood loss at a mean 1934 mL total blood, or one third of blood mass in certain patients. When bloodsaving techniques (rhEPO, scheduled autologous transfusion, iron supplementation, isovolemic preoperative hemodilution, blood recycling, antifibrinolytics) are not deployed, 80% of patients may require transfusion. While it must not be forgotten that the risks associated with non-transfusion far outweigh those of transfusion-related accidents [5, 6] , shortage of blood supplies in France and fear (often mediainduced) of homologous transfusion and its cost justify the search for new techniques of blood saving in both the surgical and medical areas.
We undertook a prospective assessment of the effect of an antifibrinolytic, tranexamic acid (Exacyl ® ), on perioperative blood loss in primary THR. Although this application is not novel in orthopedics [7] [8] [9] , it is not widespread. The originality of the study lays in the entire cohort receiving postoperative thromboprophylaxis with a recently marketed oral antiactivated-factor-X (anti-Xa), rivaroxaban (Xarelto ® ), intended to simplify prevention of thromboembolic events [10] .
The objective of study was to assess the efficacy of tranexamic acid in reducing blood loss during primary cementless THR with associated rivaroxaban thromboprophylaxis.
Material and method Patients
The origin of this single-blind prospective case-control study lays in a joint decision of the surgical and anesthesia teams to implement a tranexamic acid protocol. All cases of primary THR for osteoarthritis of the hip performed by a single surgeon (J.L.) between September 2009 and September 2010 were included. Exclusion criteria were: contra-indications for tranexamic acid (chronic ischemic pathology, history of thromboembolism, renal insufficiency) or for rivaroxaban thromboprophylaxis (severe renal insufficiency (clearance < 30 mL/min) or Child class B cirrhosis of the liver with coagulopathy).
Seventy patients were included on these criteria, divided into two groups according to date of surgery:
• group A, receiving antifibrinolytic treatment by tranexamic acid (N = 37), operated on between the beginning of January and the end of September 2010; • control group B, without tranexamic acid (N = 33), operated on between the beginning of September and the end of December 2009.
No patients were lost to follow-up or left the study; all data were included in the statistical analysis according to the original distribution between groups.
The antifibrinolytic protocol, recommended by Rosencher et al. [5] , comprised intravenous (iv) tranexamic acid administered peroperatively (at incision): 1 g iv; and postoperatively: 1 gram iv at H3, H7 and H12.
All patients had an anesthesia consultation at least 1 month before surgery. In a blood-saving strategy, those with hemoglobinemia less than 12 g/dL received an injection of 40,000 IU rhEPO (human recombinant erythropoietin). Those with hemoglobinemia less than 11 and less than 10 g/dL on the day of consultation received respectively two and three injections (one injection per week) of 40,000 IU rhEPO before surgery associated to oral iron supplementation (200 mg/d) up to the surgery day. Antiplatelet therapy was systematically interrupted 5 days before surgery and resumed on postsurgical day 1.
Surgical technique, anticoagulants, transfusion policy
All THRs were performed by a single experienced surgeon (J.L.) and anesthesia team, under spinal anesthesia. The standardized procedure used a minimally invasive posterior approach and cementless implants: Corail TM stem, with Pinnacle TM alumina/alumina cup in 23 patients of group A and 18 patients of group B, or Gyros TM (Depuy, Saint Priest, France) steel/polyethylene dual mobility cup in patients over 75 years of age (14 in group A, 15 in group B). Postoperative drainage, equally standardized, used one intra-articular and one subcutaneous size-10 Redon drains, fitted at the end of the operation. Both were removed once the more productive was draining ≤ 60 mL/24hr, or by day 5 at the latest except in case of particular complications.
All patients underwent functional rehabilitation with one of the department's physiotherapists, with transfer to wheelchair as of D1 and resumption of walking as of D2.
Preventive oral anticoagulant therapy using rivaroxaban (Xarelto ® ) 1 tab per day was initiated 6 to 8 hours postoperatively for 30 days.
Transfusion policy followed Société Française d'Anesthésie Réanimation (SFAR) guidelines: autologous packed red blood cell (PRBC) transfusion in case of hemoglobinemia less than 7 g/dL in patients with no relevant history, 8-9 g/dL in case of cardiovascular history, and 10 g/dL in case of clinical intolerance for lower concentrations, acute coronary insufficiency or proven cardiac insufficiency. Oral iron supplementation was initiated at D1 or D5 when hemoglobinemia was less than 10 g/dL. All patients were checked up at 3 months postoperatively.
Assessment
The following data were systematically collected:
• To assess intergroup homogeneity: age; gender; weight;
American Society of Anesthesiologists (ASA) score [11] ; type of anesthesia; surgery time; and anticoagulant therapy (Table 1 ). • To assess tranexamic acid action: per-and postoperative blood effusion volume; real blood loss; need for PRBC transfusion; hemoglobinemia at D0 (preoperative), D1 and D5; and complications: hematoma, thromboembolic or ischemic events, and known adverse side effects of tranexamic acid (where administered). All data were recorded by an independent investigator, other than the surgeon or the anesthetist.
The studies of hemorrhage during orthopedic surgery published by Rosencher et al. [4, 5] showed that blood loss cannot be reduced to per-and postoperative volumes, which, in addition to inherent measurement biases, amount to no more than two-thirds of real blood loss.
Real blood loss was therefore calculated from the standard formula: Real blood loss = TBV × (Ht D 0 -Ht D 5 ) + transfusion volume.
The result, in milliliters of 100% hematocrit, represents loss of red blood cells rather than of total blood (including plasma and other formed elements). Total blood volume (TBV) is the volume of circulating blood: i.e., body weight (kg) × 65 mL/kg for women and 70 mL/kg for men; Ht D 0 is the preoperative hematocrit value, and Ht D 5 the hematocrit at postoperative day 5. Transfusion volume was 150 mL 100% blood for homologous and 100 mL for autologous transfusion.
Statistics
The principle assessment criteria were real blood loss, effusion volume and delta hemoglobinemia between D0 and D5. Statistical analysis used Statplus TM software (AnalystSoft Inc., Vancouver, Canada). Quantitative variables were analyzed by comparison of means using the Student t-test (equal variances), t-test for unequal variances and Mann-Whitney test (independent groups); qualitative variables were analyzed by Fisher test. The significance threshold was set at P < 0.05.
Results

Study population
Group A (tranexamic acid) comprised 37 patients: 25 women, 12 men; mean age, 69 years (Table 1) . Three were graded ASA 1, 32 ASA 2 and two ASA 3. Six were receiving antiplatelet therapy (Kardegic ® 75 mg (acetylsalicylic acid)). Mean surgery time was 81 min (range, 50 to 120 min). There were two peroperative complications: one acetabular fracture requiring autograft, a Kerboull cross plate and cementing of one cup; and one femoral shaft crack requiring complementary osteosynthesis by cerclage. There were no postoperative complications, although (Table 1) . Two were graded ASA 1, 28 ASA 2 and three ASA 3. Six were receiving antiplatelet therapy (Kardegic ® 75 mg [acetylsalicylic acid]). Mean surgery time was 83 min (range, 65 to 120 min). There were no peroperative complications. Redon drains were removed at D2, D3, D4 and D5 for respectively six, 13, 12 and two patients.
In both groups, thromboprophylaxis used Xarelto ® alone. Antiplatelet therapy was systematically interrupted 5 days before surgery and resumed at postoperative day 1. No thromboembolic complications were observed at discharge or 3-months follow-up.
Assessment of blood loss
Mean peroperative bleeding was 227 mL and 229 mL in groups A and B, respectively: i.e., no significant difference (P = 0.9529) ( Table 2 ). Mean postoperative bleeding was 440.5 mL and 641.8 mL in groups A and B, respectively: this 209 mL difference was statistically significant (P = 0.0002) ( Table 3 ).
Analysis of hemoglobinemia variation between D0, D1 and D5
Mean hemoglobinemia at D0 was 14.15 g/dL in group A, and 14.14 g/dL in group B (P = 0.47); at D1, 11.41 g/dL vs. 10.51 g/dL (P = 0.002); and at D5,11.05 g/dL vs. 10.24 g/dL (P = 0.002) ( Table 4 ). Mean D0-D5 difference was 3.1 g/dL (range, 1.5 to 5 g/dL) in group A and 3.893 g/dL (range, 1 to 6 g/dL) in group B: this 0.796 g/dL difference in favor of group A was statistically significant (P = 0.001) ( Table 5) .
Maximum difference in hemoglobinemia with respect to D0 was 3.156 g/dL (range, 1.5 à 4.8 g/dL) in group A and 4.130 g/dL in group B (range, 1.5 to 6 g/dL): this 0.965 g/dL difference in favor of group A was statistically significant (P = 0.0001) ( Table 6 ).
Analysis and management of real blood loss
In group A, mean real blood loss in mL 100% hematocrit was 414.63, versus 587.63 mL in group B (Table 7) : this 173 mL difference was statistically significant (P = 0.0006).
In group A, no PRBC transfusions were required. Four patients received oral iron and folic acid supplementation. In group B, there were four transfusions: one immediate postoperative autologous transfusion of one unit PRBC, and three homologous transfusions of two units at D2, two units at D2, D6 and D10, and two units at D6, due to hemoglobinemia at the lower limit or poor clinical tolerance. These results, however, showed no statistically significant Difference (in mL) -173 mL F-test for equal variances P = 0.0074 t-test for unequal variances P = 0.0006 Mann-Whitney (independent groups) P = 0.00015 
Discussion
To the best of our knowledge, this is the first prospective study of the effect of tranexamic acid associated to a new generation oral anticoagulant in primary total hip replacement. One gram iv Exacyl ® at incision then postoperatively at H3, H7 and H12 significantly reduced blood loss without increasing the risk of clinically symptomatic thromboembolic events in primary cementless THR with rivaroxaban thromboprophylaxis. There was a significant benefit in the tranexamic acid group in terms of postoperative bleeding (440 ml vs. 642 mL) and blood loss in mL 100% hematocrit (corresponding to real erythrocyte loss) (414.6 vs. 587.6). In contrast, there was no significant difference in peroperative effusion (227 mL vs. 229 mL). The theoretical risk with a lysine-analog antifibrinolytic such as tranexamic acid is thrombosis [5, 12] . The present study found no deep venous thrombosis or clinically symptomatic pulmonary embolism during hospital stay or at 3 months follow-up. However, given this lack of suggestive clinical signs, no imaging was prescribed which might have shown up infraclinical venous thrombosis, except in two group-A patients in whom echo-Doppler ruled out this diagnosis. The study design excluded patients at risk of thromboembolic or ischemic complications, and only low-risk patients underwent the concomitant oral anti-Xa thromboprophylaxis. This introduced a systematic underestimation of thromboembolic risk by excluding high-risk cases, which is an important study limitation. There were only two minor adverse effects (nausea) implicating tranexamic acid treatment, which was terminated after the second injection.
This prospective diagnostic study could not be randomized or performed under double-blind. Patients signed no particular consent form and no ethics committee or EudraCT (European Union Drug Regulating Authorities Clinical Trials) registration was made. Several factors, however, limited the risk of first or second order bias: good intergroup homogeneity, single-center single-operator management, and data collection by an investigator independent of the surgeon. The short period required for data harvesting avoided any follow-up bias, as no patients were lost to follow-up; it was still possible for the data of the two patients who did not receive the entire tranexamic acid treatment due to an adverse effect to be taken into account for their original group.
Blood-loss assessment in terms of effusion volume was maintained in the study out of ''surgical habit'' and to allow comparison with previous studies and current practice. But, it is probably the worst way of making assessment and comparison, despite being still very common [13] . Rigorous reproducible measurement of effusion volume is difficult and subject to strong observer bias, and the method fails to take account of blood loss by extraversion or hematoma formation, which may in fact represent up to one third of bleeding [13] . The method should no longer be used for quantifying blood loss, and we prefer to calculate red bloodcell loss, a true measure of blood loss which we refer to as ''real blood loss''. The study did not take account of effects due to anesthetic substances and filling fluids [14] ; anesthesia, however, was performed by a single team for all 70 patients, so that its impact can be assumed to have been homogeneous.
The present results confirm the literature data on the efficacy of tranexamic acid in reducing postoperative blood loss, improving D5 hemoglobinemia and reducing resort to transfusion [15] [16] [17] [18] [19] [20] . Recent studies, including several metaanalyses, further reported improvement in peroperative effusion, not confirmed by the present study [18, 19, [21] [22] [23] .
A literature search, however, retrieves studies that are hard to compare [18, [23] [24] [25] . Populations are not matchable, and surgical management varies widely (indications, approach, type of implant, blood-saving strategy, anesthesia management, tranexamic acid injection schedule), as does thromboembolism risk prevention. Studies are rarely randomized with double blind, and series are often less than 50 patients. The present study highlights the efficacy of and tolerance for rivaroxaban thromboprophylaxis in primary THR [10] , without clinical thrombotic events when tranexamic acid is associated [17, 21, 26, 27] .
The study confirms the efficacy of tranexamic acid in reducing blood loss in primary THR without elevated thromboembolic risk if contra-indications are observed. It further demonstrated that such efficacy and safety persisted when associated to thromboprophylaxis by rivaroxaban, the ease of use of which will probably lead to it replacing classical heparin-type anticoagulants in the years to come. Moreover, in this period of budgetary restrictions, the cost of tranexamic acid (2 Euros for 2 g) compared to classic methods [19, [25] [26] [27] is a convincing argument, especially as Zufferey et al. [20] clearly showed the cost/benefit ratio ( Table 8) .
A prospective double-blind study of time to resumption of walking, hospital stay and resultant costs could provide a quantitative basis to the role of tranexamic acid in hip implant surgery. The present results encourage us to examine the use of tranexamic acid in THR revision, the frequency of which, with the associated elevated hemorrhage risk, is liable to increase following demographic trends in France.
